Try our Advanced Search for more refined results
Life Sciences
-
December 06, 2023
Edwards Loses Battle To Defend Heart-Valve Patent At EPO
The European Patent Office has revoked one of the patents of Edwards Lifesciences Corp. for prosthetic heart valve technology, jeopardizing its infringement battles in multiple countries.
-
December 05, 2023
Philips Settles Claim Rival's Worker Hacked Ultrasound Tech
A California federal judge on Monday tossed Philips North America's copyright suit alleging a competitor's former employee stole ultrasound technology by hacking into its software, after the parties agreed to settle the dispute last week.
-
December 05, 2023
Ex-CEOs Must Face Claims They Pilfered Bioscience Co.'s IP
Two former CEOs of Global Discovery Biosciences Corp. can't dodge claims that they cost the company an opportunity to develop new medical tests by siphoning the resources to another company, a Delaware Chancery Court judge has said.
-
December 05, 2023
Patent Board Says Goodnight To NYU's Sleep Machine Patents
Judges on the Patent Trial and Appeal Board dealt a blow to two patents owned by New York University, which is currently suing a San Diego company over technology allegedly used by a brand of small machines sold to treat sleep disorders.
-
December 05, 2023
Texas Sued By Pregnant Woman Seeking Abortion Care
A Texas woman who says she is suffering pregnancy complications sued the Lone Star State on Tuesday seeking to block its abortion bans, so she may terminate a nonviable fetus, in what an advocacy group believes is a first-of-its-kind case since the U.S. Supreme Court decided Roe v. Wade in 1973.
-
December 05, 2023
Group Says US Gov't Must Address Drug 'Patent Thickets'
A nonprofit group with a history of examining the U.S. drug patent system released a new blueprint on Tuesday aimed at addressing the use of patent thickets by pharmaceutical companies that allegedly drive up prices for prescription drugs.
-
December 05, 2023
Abbott Labs Says Sales Exec Fired Due To Attitude, Not Age
Abbott Laboratories told a New Jersey federal jury on Tuesday that a former sales director was terminated after over 20 years at the company because of his dismissiveness toward change and feedback on his work — not because of how old he was at the time.
-
December 05, 2023
Mintz Bolsters Healthcare Practice With Wiley Partner
After spending almost two full decades at Wiley Rein LLP, health law attorney Rachel A. Alexander is taking her talents to Mintz Levin Cohn Ferris Glovsky and Popeo PC, the firm announced Monday.
-
December 05, 2023
Ex-Hospital CFO, 3 Doctors Settle Kickback Case For $880K
A former hospital finance chief and three doctors in Texas will pay a total of more than $880,000 to the government to settle its allegations that they were involved in a kickback scheme to steer patients to specific laboratories for testing, the U.S. Department of Justice revealed this week.
-
December 05, 2023
Senators Debate Reimbursement Ideas To Fix Drug Shortages
Hospitals and other healthcare providers have little incentive to choose the most reliable manufacturers when buying generic drugs, exacerbating the risk of shortages that threaten patients' lives, experts told U.S. senators on Tuesday.
-
December 05, 2023
Bristol-Myers Decries Blue Cross Unit's Last-Minute Dropout
Celgene and parent Bristol-Myers Squibb expressed frustration Tuesday about the timing of a Blue Cross unit's decision to bow out as a plaintiff in New Jersey federal court antitrust litigation accusing the drugmakers of delaying generic competition to blockbuster cancer treatments, raising concerns the insurer might shirk its discovery obligations.
-
December 05, 2023
Court Denies Duty-Free Treatment For Specialty Baby Formulas
A specialty baby formula maker couldn't convince the U.S. Court of International Trade that its products could enter the country duty-free, after the court determined that the products were "food preparations" subject to a 6.4% tariff.
-
December 05, 2023
PTAB To Eye Hormone Drug Again In Patent Fight
The Patent Trial and Appeal Board has agreed to look into whether various claims in a pair of patents owned by a biotechnology maker are invalid, the latest event in a larger intellectual property fight over a treatment for a hormonal disorder.
-
December 05, 2023
Drug Co. Aceragen OK'd For Chancery-Overseen Liquidation
Biopharmaceutical company Aceragen Inc. secured a Delaware Court of Chancery go-ahead for its bankruptcy-alternative liquidation under a court-supervised assignment for the benefit of creditors in favor of a NovaQuest Capital Management affiliate.
-
December 04, 2023
PacBio Sees Most Of Its In-House Legal Dept. DQ'd In IP Row
A California federal judge on Monday disqualified all but one of Pacific Biosciences' in-house attorneys and legal support staff from working on a patent infringement case against the biotechnology company, adopting PacBio's proposed measures after the judge disqualified a former Perkins Coie LLP attorney last month.
-
December 04, 2023
Tenn. Seeks To Bar HHS Title X Denial Over Abortion Stance
Tennessee Attorney General Jonathan Skrmetti said the U.S. Department of Health and Human Services is overstepping its power by asking clinics that want Title X funding to refer patients for abortions that are illegal in the state, according to a motion filed in Tennessee federal court.
-
December 04, 2023
Pa. Court Told Overdose Prevention Org. Has Religious Views
An attorney for an overdose prevention nonprofit told a Pennsylvania federal judge Monday that the government is seeking a ruling that would force drug users onto the street and violate the Philadelphia nonprofit's right to exercise its religious beliefs.
-
December 04, 2023
Fed. Circ. Not Sure It Should Answer PREP Immunity Question
Puritan Medical Products told the Federal Circuit it's immune from a rival's patent suit over COVID-19 test swabs due to a law that shields certain activity aimed at resolving the spread of a disease during a public health emergency, but the panel didn't seem sure it was its place to decide.
-
December 04, 2023
Wash. Judge Nixes HDT's $950M mRNA Vax Trade Secrets Suit
A Washington federal judge has thrown out Seattle-based biotechnology company HDT Bio's nearly billion-dollar lawsuit accusing an Indian pharmaceutical firm of ripping off its mRNA platform to develop a new COVID-19 vaccine, at least for now, a docket entry showed Monday.
-
December 04, 2023
Dickinson Wright Adds Lewis Brisbois IP Atty In Denver
Dickinson Wright PLLC bolstered its intellectual property and commercial litigation practice through the addition of a member at its new Denver office from Lewis Brisbois Bisgaard & Smith LLP, the firm announced Monday.
-
December 04, 2023
Seagen Looks To Revive Cancer Drug Claims In Daiichi Fight
U.S. biotech company Seagen Inc. will look to revive its claims seeking billions of dollars in damages in a dispute with Japanese drugmaker Daiichi Sankyo Co. Ltd. over cancer drug patents, arguing that an arbitrator disregarded the "language and essence" of an underlying collaboration agreement.
-
December 04, 2023
Leave The Courtroom Doors Open, Says Apple Foe
Apple and lawyers for a small startup that accuses the tech giant of illegally blocking it from the smartwatch marketplace are fighting over how accessible a key hearing in the case will be.
-
December 04, 2023
Justice Jackson Skeptical Of Sacklers' Ch. 11 Liability Shield
As Purdue Pharma LP and its creditors pushed the U.S. Supreme Court on Monday to bless liability releases granted to members of the Sackler family who own it, a skeptical Justice Ketanji Brown Jackson said it was the owners themselves who created the necessity in the first place by withdrawing billions of dollars from the business before its bankruptcy.
-
December 04, 2023
Parents Want Abbott Docs On Calif. Law In Baby Formula MDL
Parents who are suing over contaminated Similac infant formula have asked an Illinois federal judge to force manufacturer Abbott Laboratories to produce documents related to its opposition to a California bill that would have required that formula be tested for heavy metals.
-
December 04, 2023
Justices Take Cautious Look At Sacklers' Purdue Immunity
U.S. Supreme Court justices on Monday challenged a bankruptcy watchdog's position that members of the Sackler family shouldn't get a liability shield in Purdue's Chapter 11 plan, focusing discussion on why such immunity might never be appropriate in the most foundational bankruptcy dispute to make it to the high court in several years.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
How Purdue High Court Case Will Shape Ch. 11 Mass Injury
The U.S. Supreme Court's recent arguments in Harrington v. Purdue Pharma, addressing the authority of bankruptcy courts to approve nonconsensual third-party releases in Chapter 11 settlement plans, highlight the case's wide-ranging implications for how mass injury cases get resolved in bankruptcy proceedings, says George Singer at Holland & Hart.
-
Opinion
Legal Profession Gender Parity Requires Equal Parental Leave
To truly foster equity in the legal profession and to promote attorney retention, workplaces need to better support all parents, regardless of gender — starting by offering equal and robust parental leave to both birthing and non-birthing parents, says Ali Spindler at Irwin Fritchie.
-
Managing ANDA Venue Issues As Del. And NJ Filings Rise
Delaware and New Jersey have prevailed as the primary forum for pharmaceutical litigation as more generic companies file abbreviated new drug applications, but this venue scheme presents traps for the unwary, and legislation may still be necessary to ensure fairness and predictability, say Timothy Cook and Kevin Yurkerwich at WilmerHale.
-
Series
Writing Thriller Novels Makes Me A Better Lawyer
Authoring several thriller novels has enriched my work by providing a fresh perspective on my privacy practice, expanding my knowledge, and keeping me alert to the next wave of issues in an increasingly complex space — a reminder to all lawyers that extracurricular activities can help sharpen professional instincts, says Reece Hirsch at Morgan Lewis.
-
What Lawyers Must Know About Calif. State Bar's AI Guidance
Initial recommendations from the State Bar of California regarding use of generative artificial intelligence by lawyers have the potential to become a useful set of guidelines in the industry, covering confidentiality, supervision and training, communications, discrimination and more, say attorneys at Debevoise.
-
Industry Must Elevate Native American Women Attys' Stories
The American Bar Association's recent research study into Native American women attorneys' experiences in the legal industry reveals the glacial pace of progress, and should inform efforts to amplify Native voices in the field, says Mary Smith, president of the ABA.
-
The Fed. Circ. In Nov.: Factual Support And Appellate Standing
The Federal Circuit's recent Allgenesis Biotherapeutics v. Cloud Break Therapeutics decision shows that appellate standing requires specific factual support, underscoring the necessary requirements for a patent challenger in an appeal from an inter partes review at the U.S. Patent and Trademark Office, say Jeremiah Helm and Sean Murray at Knobbe Martens.
-
White House Activity Is A Band-Aid For Regulating AI In Health
In the medium term, recent White House actions will have a greater impact on AI in the health care industry than Congress' sluggish efforts to regulate it, but ultimately legislation of AI's development and use in the health space will fall to Congress, say Wendell Bartnick and Vanessa Perumal at Reed Smith.
-
Understanding Discovery Obligations In Era Of Generative AI
Excerpt from Practical Guidance
Attorneys and businesses must adapt to the unique discovery challenges presented by generative artificial intelligence, such as chatbot content and prompts, while upholding the principles of fairness, transparency and compliance with legal obligations in federal civil litigation, say attorneys at King & Spalding.
-
Kochava Ruling May Hint At Next Privacy Class Action Wave
The Southern District of California's recent ruling in Greenley v. Kochava and increasing complaints alleging that a consumer website is an illegal “pen register” due to the use of third-party marketing software tools foreshadow a new theory of liability for plaintiffs in privacy litigation, say attorneys at Crowell & Moring.
-
Forecasting The Impact Of High Court Debit Card Rule Case
John Delionado and Aidan Gross at Hunton consider how the U.S. Supreme Court's forthcoming ruling in a retailer's suit challenging a Federal Reserve rule on debit card swipe fees could affect agency regulations both new and old, as well as the businesses that might seek to challenge them.
-
Series
ESG Around The World: Mexico
ESG has yet to become part of the DNA of the Mexican business model, but huge strides are being made in that direction, as more stakeholders demand that companies adopt, at the least, a modicum of sustainability commitments and demonstrate how they will meet them, says Carlos Escoto at Galicia Abogados.
-
Opinion
FDA And Companies Must Move Quickly On Drug Recalls
When a drug doesn't work as promised — whether it causes harm, like eyedrops recalled last month by the U.S. Food and Drug Administration, or is merely useless, like a widely used decongestant ingredient recently acknowledged by the agency to be ineffective — the public must be notified in a timely manner, says Vineet Dubey at Custodio & Dubey.
-
The Case For Post-Bar Clerk Training Programs At Law Firms
In today's competitive legal hiring market, an intentionally designed training program for law school graduates awaiting bar admission can be an effective way of creating a pipeline of qualified candidates, says Brent Daub at Gilson Daub.
-
Opinion
A Telecom Attorney's Defense Of The Chevron Doctrine
The Chevron doctrine, which requires judicial deference to federal regulators, is under attack in two U.S. Supreme Court cases — and while most telecom attorneys likely agree that the Federal Communications Commission is guilty of overrelying on it, the problem is not the doctrine itself, says Carl Northrop at Telecommunications Law Professionals.